Trial Profile
Phase 2b study of AD04 in patients with alcohol use disorder with selected genotypes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2023
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Alcoholism
- Focus Registrational; Therapeutic Use
- 06 Mar 2023 According to an ADial Pharmaceuticals media release, based on results from this and ONWARD trial and after discussions with its regulatory advisors and key opinion leaders (KOLs), the company believes there is a clear, cost-effective path toward FDA approval that it plans to aggressively pursue.
- 16 Apr 2020 Results published in the Adial Pharmaceuticals Media Release.
- 10 Jan 2019 Results published in the Adial Pharmaceuticals Media Release